eidx-ex991

Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

SAN FRANCISCO, October 31, 2019 — Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the company’s recent achievements, upcoming events and chief financial officer transition plan.

“We continue to focus on executing our Phase 3 program studying AG10 in patients with transthyretin (TTR) amyloidosis (ATTR). Our phase 3 study in ATTR-cardiomyopathy (ATTR-CM) is enrolling patients in the US and Europe. We look forward to presenting data from the Phase 2 open label extension study at the American Heart Association (AHA),” said Neil Kumar, Ph.D., chief executive officer of Eidos. “In addition, we executed a partnership with Alexion this quarter to develop and commercialize AG10 in Japan. This partnership brings regional resources and expertise to accelerate AG10’s development path in Japan.”

Eidos also announced the transition plan of Christine Siu, chief financial officer. Ms. Siu will remain chief financial officer of Eidos until December 31, 2019, when she will transition to a senior role at Eidos’ parent company, BridgeBio. Franco Valle, Eidos’ current vice president of finance, is expected to continue leading financial operations as senior vice president of finance and principal accounting officer thereafter. “On behalf of the entire Board and executive team, I would like to thank Christine for her contributions and leadership since we founded Eidos in 2016. She has played an invaluable role in transforming the company since its founding and I look forward to continue working together at BridgeBio,” said Dr. Kumar, chief executive officer of Eidos and BridgeBio. “It has been a rewarding experience to serve as the CFO of Eidos,” said Ms. Siu. “I am proud of the Eidos team and the progress we have made bringing AG10 closer to ATTR patients in need. I believe Eidos has great potential and I look forward to continue working with the team through the parent company, BridgeBio.”

Cash and cash equivalents totaled $165.8 million at September 30, 2019 compared with $157.1 million at December 31, 2018.

Eidos reported a net income attributable to common stockholders of $6.9 million or $0.19 per common share, for the third quarter of 2019, as compared to a net loss attributable to common stockholders of $10.6 million or $0.30 per common share for the third quarter of 2018. The increase in net income attributable to common stockholders was driven primarily by revenue received from Alexion offset by research and development expenses related to AG10 clinical trials and other pre-clinical studies, and general and administrative expenses for operations.

Research and development expenses for the third quarter of 2019 were $12.0 million, as compared to $8.4 million for the same period in the prior year. Research and development expenses for the period included costs related to contract manufacturing, and the preparation for, and the increase in, activity related to our clinical trials.

General and administrative expenses for the third quarter of 2019 were $6.0 million, as compared to $2.6 million for the same period in the prior year. The increase in general and administrative expense in these periods was due primarily to an increase in one-time charges, professional service fees, salaries and employee-related expense primarily due to an increase in headcount to support the growth of our operations, and other administrative expenses.

Eidos reported a net loss attributable to common stockholders of $18.9 million or $0.52 per common share, for the nine months ended September 30, 2019, as compared to a net loss attributable to common stockholders of $30.0 million or $1.83 per common share for the nine months ended September 30, 2018. The increase in net loss attributable to common stockholders was driven primarily by research and development expenses related to AG10 clinical trials and other pre-clinical studies, and general and administrative expenses for operations.

Research and development expenses for the nine months ended September 30, 2019 were $33.0 million, as compared to $20.2 million for the same period in the prior year. Research and development expenses for the period included costs related to contract manufacturing, and the preparation for, and the increase in, activity related to our clinical trials.

General and administrative expenses for the nine months ended September 30, 2019 were $12.3 million, as compared to $6.9 million for the same period in the prior year. The increase in general and administrative expense in these periods was due primarily to an increase in professional service fees, salaries and employee-related expense primarily due to an increase in headcount to support the growth of our operations, and other administrative expenses.

AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in subjects with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated >90% average TTR stabilization at day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner. AG10 is currently being studied in an open-label extension of a Phase 2 clinical trial in patients with ATTR-CM, and patient enrollment is ongoing for a Phase 3 clinical trial of AG10 in patients with ATTR-CM (ATTRibute-CM).

AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a rescue mutation because co-inheritance has been shown to prevent ATTR in individuals also inheriting a pathogenic, or disease-causing, mutation in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the stabilizing structure of this rescue mutation.

ATTR represents a significant unmet medical need with a large patient population and an inadequate current standard of care. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into three distinct categories: wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each disease is approximately 400,000 patients, 40,000 patients and 10,000 patients, respectively.

All three forms of ATTR are progressive and fatal. For patients with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in life (age 50+), with median survival of three to five years from diagnosis. ATTR-PN either presents in a patient's early 30s or later (age 50+), and results in a median life expectancy of five to ten years from diagnosis. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care.

Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR. For more information, please visit www.eidostx.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act. All statements other than statements of historical facts, including the statements about the potential therapeutic and clinical benefits of AG10, the potential to accelerate the development and registration of AG10, our ability to enroll patients in and conduct the ATTRibute-CM trial in accordance with our plans, our plan to initiate a Phase 3 study of AG10 in ATTR-PN, our ability to generate data from the open label extension of our Phase 2 study of AG10 in ATTR-CM, future clinical and regulatory milestones of AG10, our chief financial officer transition plan, the timing of these events, the indications we intend to pursue and our possible clinical or other business strategies, and our ability to fund our clinical development plans, are forward-looking statements. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. These forward-looking statements are based on our management’s current beliefs and assumptions about future events and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: our limited operating history and historical losses, our liquidity to fund the development of AG10 through current and future milestones, our ability to raise additional funding to complete the development of AG10, our dependence on the success of AG10, our ability to enroll patients in the ATTRibute-CM trial, results from our clinical trials and pre-clinical studies and those of third parties working in the same area as our product candidate, our ability to advance AG10 in clinical development in accordance with our plans, and our dependence on third parties in connection with our manufacturing, clinical trials and pre-clinical studies. Additional risks and uncertainties that could affect our future results are included in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, to be filed with the Securities and Exchange Commission concurrently herewith. Additional information on potential risks will be made available in other filings that we make from time to time with the SEC. In addition, any forward-looking statements contained in this press release are based on assumptions that we believe to be reasonable as of this date. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.


		Three Months Ended							Nine months ended
		September 30,							September 30,
		2019			2018				2019				2018
License revenue	$		26,691	$		-		$		26,691		$		-
Operating expenses*:
Cost of license revenue			2,500			-				2,500				-
Research and development			11,987			8,369				33,033				20,216
General and administrative			5,953			2,619				12,285				6,858
Total operating expenses			20,440			10,988				47,818				27,074

Income (loss) from operations			6,251			(10,988	)			(21,127	)			(27,074	)
Other income (expense), net			680			374				2,272				(3,797	)

Net income (loss) and comprehensive income (loss)			6,931			(10,614	)			(18,855	)			(30,871	)

Deemed dividend related to redemption feature embedded in Convertible Promissory Notes payable to stockholders			-			-				-				(6,523	)
Gain on extinguishment of Convertible Promissory Notes payable to stockholders			-			-				-				7,436

Net income (loss) attributable to common stockholders	$		6,931	$		(10,614	)	$		(18,855	)	$		(29,958	)
Net income (loss) per share attributable to common stockholders, basic	$		0.19	$		(0.30	)	$		(0.52	)	$		(1.83	)
Net income (loss) per share attributable to common stockholders, diluted	$		0.18	$		(0.30	)	$		(0.52	)	$		(1.83	)
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic			36,581,786			35,965,790				36,356,675				16,361,349
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, diluted			37,710,734			35,965,790				36,356,675				16,361,349

* Includes stock-based compensation as follows
Research and development	$		626	$		251		$		1,630		$		872
General and administrative			969			443				2,095				829
Total stock-based compensation expense	$		1,595	$		694		$		3,725		$		1,701

	September 30,			December 31,
	2019			2018
Assets
Current assets:
Cash and cash equivalents	$	165,822		$	157,147
Related party receivable		83			34
Prepaid expenses and other current assets		5,402			1,789
Total current assets		171,307			158,970
Property and equipment, net		1,199			209
Operating lease, right of use asset		4,121			-
Other assets		2,267			933
Total assets	$	178,894		$	160,112
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	3,567		$	1,956
Related party payable		372			256
Lease liabilities		471			-
Accrued expenses and other current liabilities		5,665			2,577
Total current liabilities		10,075			4,789
Other liabilities		129			316
Lease liabilities, non-current		4,736			-
Total liabilities		14,940			5,105

Stockholders’ equity:
Preferred stock		-			-
Common stock		38			37
Additional paid-in capital		248,041			220,240
Accumulated deficit		(84,125	)		(65,270	)
Total stockholders’ equity		163,954			155,007
Total liabilities and stockholders’ equity	$	178,894		$	160,112